drugset

drugset / Trial / NCT00452257

A Study of Enzastaurin in Patients With Leukemia

NCT00452257 ↗

Phase 1 Completed 18 enrolled Eli Lilly and Company

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to see if enzastaurin affects the pGSK3 beta level in B-cell chronic lymphocytic leukemia (B-CLL) cells.

Timeline

Start: 2007-05
Primary completion: 2008-09
Completion: 2008-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	enzastaurin	Small molecule	500 mg	Oral

Indications